Wysliva Tablet, containing 200 mg of Xylitol, is a pharmaceutical formulation primarily utilized for its therapeutic benefits in dental health and metabolic regulation. Xylitol, a naturally occurring sugar alcohol, exhibits significant efficacy in reducing dental caries by inhibiting the growth of Streptococcus mutans, thereby promoting oral hygiene and preventing tooth decay. Additionally, Xylitol is known for its low glycemic index, making Wysliva Tablet a suitable adjunct in managing blood glucose levels in diabetic patients. The tablet is indicated for use as a sugar substitute in individuals requiring controlled carbohydrate intake, contributing to improved metabolic control without compromising taste or caloric intake. Wysliva is well-tolerated with minimal adverse effects, although excessive consumption may lead to gastrointestinal disturbances such as bloating or diarrhea due to its osmotic properties. The recommended dosage should be adhered to as per medical advice to optimize therapeutic outcomes. Wysliva Tablet is contraindicated in patients with known hypersensitivity to sugar alcohols. It is essential to maintain regular dental hygiene practices alongside the use of this medication to achieve comprehensive oral health benefits. Consultation with a healthcare professional is advised prior to initiation, especially in populations with underlying health conditions.